CD133 antisense suppresses cancer cell growth and increases sensitivity to cisplatin in vitro

The increased incidence of cancer in recent years is associated with a high rate of mortality. Numerous types of cancer have a low percentage of CD133+ cells, which have similar features to stem cells. The CD133 molecule is involved in apoptosis and cell proliferation. The aim of this study was to d...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2012-11, Vol.4 (5), p.901-905
Main Authors: BLANCAS-MOSQUEDA, MARISOL, ZAPATA-BENAVIDES, PABLO, ZAMORA-ÁVILA, DIANA, SAAVEDRA-ALONSO, SANTIAGO, MANILLA-MUÑOZ, EDGAR, FRANCO-MOLINA, MOISÉS, DE LA PEÑA, CARMEN MONDRAGÓN, RODRÍGUEZ-PADILLA, CRISTINA
Format: Article
Language:English
Subjects:
antisense RNA
Apoptosis
cancer cell lines
cancer stem cell
Cancer therapies
CD133
Cell cycle
Cell growth
cisplatin
Kinases
Medical prognosis
Metastasis
Proteins
Signal transduction
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The increased incidence of cancer in recent years is associated with a high rate of mortality. Numerous types of cancer have a low percentage of CD133+ cells, which have similar features to stem cells. The CD133 molecule is involved in apoptosis and cell proliferation. The aim of this study was to determine the biological effect of CD133 suppression and its role in the chemosensitization of cancer cell lines. RT-PCR and immunocytochemical analyses indicated that CD133 was expressed in the cancer cell lines B16F10, MCF7 and INER51. Downregulation of CD133 by transfection with an antisense sequence (As-CD133) resulted in a decrease in cancer cell viability of up to 52, 47 and 22% in B16F10, MCF-7 and INER51 cancer cell lines, respectively. This decreased viability appeared to be due to the induction of apoptosis. In addition, treatment with As-CD133 in combination with cisplatin had a synergic effect in all of the cancer cell lines analyzed, and in particular, significantly decreased the viability of B16F10 cancer cells compared with each treatment separately (3.1% viability for the combined treatment compared with 48% for 0.4 μg As-CD133 and 25% for 5 ng/μl cisplatin; P
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2012.692